분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-08-16 22:24:46 , Hit : 1167
 Using RNA to Amplify RNA

The Scientist » News & Opinion » Daily News Using RNA to Amplify RNA

Researchers apply in vitro evolution to generate an RNA enzyme capable of copying and amplifying RNA.

By Abby Olena | August 15, 2016


WIKIMEDIA, LUCASHARRRNA self-replication is a key part of the RNA world hypothesis, but generating ribozymes in the lab that can synthesize, replicate, and amplify functional RNA molecules with complex structures has proven difficult. Until now, the most successful variants of the class I RNA polymerase ribozyme have worked inefficiently even on their preferred template: short, simple RNA sequences with a high concentration of pyrimidines.

In a paper published today (August 15) in PNAS, scientists from the Scripps Research Institute in La Jolla, California, report on their use of in vitro evolution to generate an improved polymerase ribozyme that can synthesize multiple functional, structured RNAs and amplify short RNA templates.

The research “has extended the capabilities of RNA to RNA polymerization in ways that have not been achieved before,” said Scott Silverman of the University of Illinois at Urbana-Champaign, who did not participate in the work. “It’s definitely a key advance in the field of understanding what RNA polymerase ribozymes can do, and it has pretty important implications for the RNA world theory,” he added.

Study coauthors Gerald Joyce and David Horning of Scripps began with a variant of the class I RNA polymerase ribozyme. They introduced random mutations throughout its sequence to generate 100 trillion variants. Joyce and Horning then applied pressure to this population, by priming the ribozymes to complete RNA aptamers—molecules that bind to a synthetic form of vitamin B12 or to GTP. Each round, the researchers selected for ribozymes that produced functional products, products of the correct length, or both.

The researchers increased the stringency of selection for successive generations by requiring the ribozymes to synthesize longer RNA molecules in less time. By the 24th round, the population could synthesize purine-rich, functional RNA sequences.

From this population, Horning and Joyce isolated a variant of the ribozyme called 24-3, which had 17 mutations. The 24-3 polymerase used all four bases and functioned much more quickly than the starting polymerase. It was capable of copying multiple functional RNAs with complex secondary structures, including aptamers, other ribozymes, and yeast transfer RNA (tRNA). The researchers showed that 24-3 could also amplify short RNA templates exponentially in an RNA-only version of PCR.

“It’s really beautiful work and a major step towards the realization of RNA self-replication,” Philipp Holliger of the MRC Laboratory of Molecular Biology in Cambridge, U.K., who did not participate in the work, wrote in an email to The Scientist.

“What Horning and Joyce have done here is a wonderful step forward,” said Donald Burke-Agüero of the University of Missouri, who also did not participate in the research. “It puts us much closer to having an RNA replication system that can sustain replication of RNA, but it’s not there yet.”

The 24-3 polymerase ribozyme cannot copy itself, however. Although yeast tRNA is highly structured and large compared to products synthesized by earlier polymerase ribozymes, the 24-3 ribozyme is three times larger than yeast tRNA and contains even more complex structural elements.

Joyce, Horning, and colleagues are working to overcome this limitation with ongoing in vitro evolution experiments. Stricter selection criteria should prompt the ribozyme to make larger, more complicated functional products more efficiently, the researchers said, though it’s not clear how many test tube generations it will take to achieve this.

Meantime, Joyce pointed to the evolutionary biology research application of studying the evolution of a self-replicating ribozyme. “If you had an RNA enzyme that was an RNA replicase that could copy RNAs exponentially, including copies of itself, then I would say it’s alive,” said Joyce . “Then it’s up to evolution. Whatever makes it better makes it better.”

D.P. Horning and G.F. Joyce, “Amplification of RNA by an RNA polymerase ribozyme,” PNAS, doi:10.1073/pnas.1610103113, 2016.







1107   혁신적인 폐암 면역치료제를 승인한 FDA  이성욱 2015/10/06 1147
1106   5년새 20배 성장 `유전자치료제` 시장..경쟁력 확보 필수  이성욱 2016/07/21 1148
1105   혈액 암과 면역세포의 DNA 편집의 관계  이성욱 2015/09/14 1152
1104   프리온 질환을 막는 유전자 돌연변이  이성욱 2015/06/15 1157
1103   CRISPR Antidotes Galore  이성욱 2016/06/14 1159
1102   [바이오토픽] Science, 2017년 과학연구 총결산  이성욱 2017/12/27 1162
1101   암 생존율을 높일 수 있는 면역세포  이성욱 2014/12/16 1167
1100   진화와 질병치료 연구를 진전시킬 새로운 유전 메커니즘  이성욱 2015/02/06 1167
  Using RNA to Amplify RNA  이성욱 2016/08/16 1167
1098   일본의 검증팀 STAP 세포 재현 포기, 오보카타 사임  이성욱 2014/12/23 1168
1097   GSK Gets Positive CHMP Opinion For Strimvelis To Treat Rare Disease ADA-SCID  이성욱 2016/04/02 1170
1096   네안데르탈인과 이웃에 살았던 현생인류의 두개골 발견  이성욱 2015/02/03 1173
1095   CRISPR Encodes Movie into Bacteria, Then DNA Sequencing Plays It  이성욱 2017/07/14 1173
1094   microRNA가 췌장암 치료제가 될 수 있을까  이성욱 2015/06/30 1176
1093   중증 근이영양증을 치료하는 RNA 편집 기술  이성욱 2015/10/15 1177
1092   JPM서 논란 ‘유전자가위 기술’ 올해의 마일스톤은?  이성욱 2018/01/21 1177
1091   알츠하이머 질환에 대한 항체약물의 가능성  이성욱 2015/07/30 1179
1090   지방간과 흉터가 유전과 관련되어 있다?  이성욱 2015/10/05 1182
1089   옥스포드 나노포어, 휴대용 시퀀서 미니온 출시 임박  이성욱 2015/05/08 1186
1088   부모의 특징을 자식에게 전달하는 방식: 박테리아의 DNA  이성욱 2015/02/19 1187

[1][2][3][4][5][6][7][8] 9 [10]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN